Member Info for EmeraldCarrots

Momentum in ANY of the 7 countries other than the UK could make one hell of a difference here. They need publicity about stopping babies going deaf if they have a bad reaction to antobiotics. A salespersons dream come true. ONE tv mention on the news in say Italy or something and we could have take off. Genedrive could do with break!

RNS did confirm 7 Countries other then the UK are using. Countries, not Companies. There is a tad of a difference.

Tick up.

Or the Manchester University NHS Foundation Trust commencement of the 12-month Acute Coronary Syndrome and CYP2C19 rapid genotyping programme (£120k). Part of the £800K should be invoiced in October, and I should think all the £120k. As the income increases the drain on the finances will decrease. The 7 countries in addition to the UK will be interesting. In any one of these sales of one or both of the machines could take off "out of the blue". Just a magazine article, good publicity from a tv report etc.. I hope and suspect they are expecting more sales imminently.

All IMHO.

Established in the UK with the NHS. Just starting to gain clients in the EU. USA to follow. Some Plc is going to get Genedrive for next to nothing and make a fortune IMHO.

Follow in due course IMHO. Momentum building, the RNS shows that. Scottish rollout starts in 7 weeks.

Follow in due course IMHO.

"I am pleased that our year-on-year revenue growth evidences product-market fit, both in our domestic market and international territories where we are seeing initial operational and commercial traction in European countries adopting, such as Italy, Netherlands, and Middle East countries including UAE, Bahrain, Kuwait, Saudi Arabia and Qatar, and I look forward to further growth in these and other regions as we progress."

========================

This is an RNS so is checked. So they DO have clients in Italy, the Netherlands, UAE, Bahrain, Kuwait, Saudi Arabia and Qatar. There are COUNTRIES not small fry. Any one of which could turn into major revenue. 7 COUNTRIES.

Why on Earth do you post about Genedrive?

"I am pleased that our year-on-year revenue growth evidences product-market fit, both in our domestic market and international territories where we are seeing initial operational and commercial traction in European countries adopting, such as Italy, Netherlands, and Middle East countries including UAE, Bahrain, Kuwait, Saudi Arabia and Qatar, and I look forward to further growth in these and other regions as we progress."

The National Institute for Health and Care Clinical Excellence ("NICE") Early Value Assessment ("EVA") evidence generation completion and submission, which is expected to be a catalyst for wider UK implementation.

If a hospital has to buy the Genedrive CYP2C19 ID Kit for use with in point of care "ischaemic stroke or Transient Ischaemic Attack" why on Earth would the same hospital ALSO get a lab test for situations where that can wait longer and cost more? Are these people nuts? What will happen is if they have the machine they will us it for ALL CYP2C19 testing. It's obvious.

Please post a link to the doc with the guidance publication date.

Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers

https://clinicaltrials.gov/study/NCT06967961?term=parsortix&limit=25&sort=StudyFirstPostDate&rank=1

Comparison of Different Methods of CAPTure of Circulating Tumour Cells (CTC) in Patients With Metastatic Breast or Prostate Cancer

https://clinicaltrials.gov/study/NCT06904625?term=parsortix&limit=25&sort=StudyFirstPostDate&rank=2

Impact of Circadian Rhythm on the Spread of Circulating Tumor Cells in Lung Cancer Patients

https://clinicaltrials.gov/study/NCT05988970?term=parsortix&limit=25&sort=StudyFirstPostDate&rank=3

Proof-of-concept Study of Blood Markers of Tumor Dissemination in Patients with Versus Without Intestinal Polyps (EARDIS)

https://clinicaltrials.gov/study/NCT05648240?term=parsortix&limit=25&sort=StudyFirstPostDate&rank=4

Https://www.lse.co.uk/rns/AGL/eacr-2025-data-demonstrating-dna-dual-analysis-9218c5p5cpg3ebn.html

"This poster builds on work first presented in a February 2025 webinar hosted by Illumina as part of a co-marketing initiative. It showcases an end-to-end Illumina-based DNA dual analysis workflow for the analysis of CTCs harvested using ANGLE's Parsortix system, alongside circulating tumour DNA (ctDNA), using a 79-gene lung cancer panel on the Illumina NextSeq2000 platform. Illumina is the world's largest provider of NGS systems and assays, with an installed base of over 25,000 sequencing systems across more than 9,500 customers in 155 countries. The study provides a practical example of how Illumina customers could integrate DNA dual analysis of CTCs and ctDNA into existing sequencing pipelines for deeper insights into tumour heterogeneity."

"This study demonstrates ANGLE's unique ability to deliver DNA dual analysis from a single blood sample, revealing clinically relevant mutations missed by ctDNA alone. By enabling a more complete view of tumour genetics, molecular analysis of CTC-DNA and ctDNA using the Parsortix system offers biopharma partners a valuable tool for identifying resistance, stratifying patients, and improving trial outcomes."

Sales (£55,000 approx each) and associated comsumables. Also the staining kit and CellKeep™ slide are not tied to the Parsortix machine. We are in the dark about sales of these for the moment. If the cellkeep slide is as good as they claim it surely could be sold for £100 each or more.

https://angleplc.com/portrait-plus/

JimiHendrix.

Why do you post this stuff? When have you ever been correct? Is there an example?

It's rumoured Good news at that!

Someone is !!!!!!!!!!!

Hope it's good! LOL!